Literature DB >> 31628011

Dr. Daniel Acosta and In Vitro toxicology at the U.S. Food and Drug Administration's National Center for Toxicological Research.

Amy Inselman1, Fang Liu2, Cheng Wang2, Qiang Shi1, Li Pang1, William Mattes1, Matthew White3, Beverly Lyn-Cook4, Hector Rosas-Hernandez2, Elvis Cuevas2, Susan Lantz2, Syed Imam2, Syed Ali2, Dayton M Petibone5, Jennifer M Shemansky5, Rui Xiong5, Yiying Wang5, Priya Tripathi5, Xuefei Cao5, Robert H Heflich5, William Slikker6.   

Abstract

For the past five years, Dr. Daniel Acosta has served as the Deputy Director of Research at the National Center for Toxicological Research (NCTR), a principle research laboratory of the U.S. Food and Drug Administration (FDA). Over his career at NCTR, Dr. Acosta has had a major impact on developing and promoting the use of in vitro assays in regulatory toxicity and product safety assessments. As Dr. Acosta nears his retirement we have dedicated this paper to his many accomplishments at the NCTR. Described within this paper are some of the in vitro studies that have been conducted under Dr. Acosta's leadership. These studies include toxicological assessments involving developmental effects, and the development and application of in vitro reproductive, heart, liver, neurological and airway cell and tissue models. Published by Elsevier Ltd.

Entities:  

Year:  2019        PMID: 31628011     DOI: 10.1016/j.tiv.2019.03.003

Source DB:  PubMed          Journal:  Toxicol In Vitro        ISSN: 0887-2333            Impact factor:   3.500


  1 in total

1.  Non-clinical considerations for supporting accelerated inclusion of pregnant women in pre-licensure clinical trials with anti-HIV agents.

Authors:  Rick Greupink; Hedwig van Hove; Felix Mhlanga; Peter Theunissen; Angela Colbers
Journal:  J Int AIDS Soc       Date:  2022-07       Impact factor: 6.707

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.